Form 4: CEO Acquires Convertible Note in Provectus Biopharma

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $35,000.

Summary

• Edward Pershing, CEO, Director, and 10% Owner of Provectus Biopharmaceuticals, Inc. (PVCT), acquired an 8% unsecured convertible promissory note.
• The note has a principal amount of $35,000 and was acquired on October 3, 2025.
• It is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The conversion can be voluntarily elected by the reporting person at any time or will automatically occur twelve months after the issue date, on October 3, 2026.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless converted earlier.
• The note was issued pursuant to the Issuer's 2025 Financing.

Sentiment

Score: 6

Explanation: The acquisition of a convertible note by the CEO shows insider confidence and provides capital. However, it also signals ongoing financing needs and potential future dilution for common shareholders, which introduces some uncertainty.

Positives

• CEO Edward Pershing's direct investment through the acquisition of the convertible note signals insider confidence in the company's future prospects.
• The 8% interest rate on the note provides a return for the holder, indicating a structured investment opportunity.
• The transaction provides capital to Provectus Biopharmaceuticals as part of its 2025 Financing efforts.

Negatives

• The issuance of a convertible note, particularly to an insider, may suggest the company is seeking capital through non-traditional means, potentially due to challenges in securing conventional financing.
• Future conversion of the note into Series D-1 Preferred Stock and subsequently into common stock will dilute the ownership percentage of existing common shareholders.
• The conversion price of $2.862 per share for the Series D-1 Preferred Stock could set a valuation benchmark that may be lower than current market expectations or previous valuations.

Risks

• Dilution Risk: Conversion of the promissory note into Series D-1 Preferred Stock, and subsequently into common stock, will dilute the ownership percentage of existing common shareholders.
• Valuation Risk: The conversion price of $2.862 per share for the Series D-1 Preferred Stock may influence market perception of the company's equity value.
• Financing Risk: The issuance of an 8% unsecured convertible promissory note as part of a '2025 Financing' suggests ongoing funding needs or potential challenges in securing traditional equity or debt financing.

Future Outlook

The filing indicates future potential dilution from the conversion of the promissory note into Series D-1 Preferred Stock and subsequently into common stock, with specific automatic conversion dates set for October 3, 2026, for the note and June 26, 2026, for the Series D-1 Preferred Stock.

Industry Context

This transaction is a common method for early-stage or growth-stage biotechnology companies like Provectus Biopharmaceuticals to raise capital, often from insiders or strategic investors, to fund research, development, or operational expenses. Convertible notes offer flexibility and defer equity valuation until a later event.

Comparison to Industry Standards

• Issuance of convertible notes to insiders is a common practice in the biotechnology sector, particularly for companies in clinical development stages, to secure funding without immediate equity dilution or setting a definitive valuation.
• The 8% interest rate is within a reasonable range for unsecured convertible notes in the biotech industry, reflecting the risk profile of such investments.
• The conversion terms, including a fixed conversion price and automatic conversion triggers, are standard for such instruments, providing clarity on potential future equity structure.

Related Party Transactions

• The acquisition of an 8% Unsecured Convertible Promissory Note by Edward Pershing, who is the CEO, Director, and 10% Owner of Provectus Biopharmaceuticals, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock upon conversion of the note and preferred stock. The conversion price of $2.862 for preferred stock may influence valuation perception.
• Company: Receives capital from the note issuance, supporting operations or development.
• Edward Pershing (Reporting Person): Acquires an interest-bearing instrument with potential for equity upside, demonstrating increased personal stake in the company's success.

Next Steps

• Potential voluntary conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Preferred Stock by Edward Pershing at any time while the Note is outstanding.
• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 26, 2026, unless earlier converted.
• Automatic conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Convertible Preferred Stock on October 3, 2026, if not voluntarily converted earlier.

Key Dates

Recommendation

The CEO's acquisition of a convertible note signals insider confidence and provides capital to the company, which are positive indicators. However, the transaction also highlights ongoing financing needs and introduces potential future dilution for common shareholders. The specific conversion terms and the '2025 Financing' context suggest a complex capital structure that warrants a 'hold' recommendation until further clarity on the company's strategic direction and financial performance emerges.

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Convertible Note, Series D-1 Preferred Stock, Insider Transaction, Form 4, SEC Filing, Biotechnology, Financing, Dilution